A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer

Advanced non-small cell lung cancer (NSCLC) remains a difficult cancer to treat, and evolution of platinumfree regimens in a first-line setting is ongoing. This was a dose-finding study on the docetaxel and vinorelbine combination. Docetaxel was given at 60 mg/m² on day 1 only, and vinorelbine was given on days 1 and 15 starting at 20 mg/m², then escalated to 30 and 40 mg/m² in two dose cohorts. Each cycle lasted 28 days. The maximum tolerated dose was 60 mg/m² docetaxel and 30 mg/m²vinorelbine. Twenty-one patients were enrolled and showed an overall response rate of 9.5%, with stable disease documented in 33% of patients. The dosage schedule of this combination resulted in acceptable toxicities. The median time to progression was 5.86 months (95% CI 2.50-9.22), and median survival was 10.96 months (95% CI 1.42-20.51) with a 1-year survival rate of 50%. This combination may be important for patients with NSCLC.